Bivalirudin for anticoagulation in mechanical aortic valve replacement and heparin-induced thrombocytopenia

Moti Klein, Aaron Tomer, Andre Swartz, Leonid Koyffman, Natan Weksler

    Research output: Contribution to journalArticlepeer-review

    6 Scopus citations

    Abstract

    Heparin-induced thrombocytopenia (HIT) is a potentially serious syndrome. Since there are some alternatives to treatment with heparin in patients who develop HIT, the decision as to which to use should be based on renal and hepatic function, drug availability and the available monitoring resources. We report a patient who received heparin for mechanical aortic valve replacement. Her clinical course was complicated by HIT, which was treated initially by danaparoid. The syndrome progressed with new thrombotic complications, and eventually was treated successfully by bivalirudin (Angiomax; Medison Pharma Ltd, Petach Tikva, Israel) for 9 days. We propose that treatment with bivalirudin for several days is a safe and effective alternative to heparin therapy in patients who develop HIT.

    Original languageEnglish
    Pages (from-to)331-333
    Number of pages3
    JournalBlood Coagulation and Fibrinolysis
    Volume17
    Issue number4
    DOIs
    StatePublished - 1 Jan 2006

    Keywords

    • Bivalirudin
    • Heparin-induced thrombocytopenia
    • Thrombosis

    ASJC Scopus subject areas

    • Hematology

    Fingerprint

    Dive into the research topics of 'Bivalirudin for anticoagulation in mechanical aortic valve replacement and heparin-induced thrombocytopenia'. Together they form a unique fingerprint.

    Cite this